Month: September 2026

CONWAY, Ark., Sept. 18, 2026 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NYSE: HOMB) (“Home” or “the Company”), parent company of Centennial Bank (“Centennial”), today announced two recent performance recognitions.

First, on September 9, 2026, Forbes published their “World’s Top Performing Banks” list, and HOMB ranked #5 in Mid-Size Banks. Banks were evaluated across four main dimensions: profitability, growth & earnings quality, capital & funding resilience and asset quality & efficiency. Eligible banks were segmented into six tiers based on their total assets and then the scores were assigned. HOMB is among Tier 4 (mid-size banks) which have $20-$50 billion in assets. This is a new ranking by Forbes, and it is predicated on objective financial data obtained through leading data providers, such as S&P Capital IQ platform.

Second, on August 21, 2026, Bank Director published their annual “RankingBanking”, The Best U.S. Banks study, sponsored by Crowe LLP., and HOMB ranked #9 in the $5-$50 billion asset group and #18 among the top 25 publicity traded banks in the country. Data used in the 2026 RankingBanking analysis of the 300 largest publicly traded banks was collected through S&P Global Market Intelligence and analyzed by Piper Sandler & Co., using calendar year 2025 results. Four metrics were used to assess profitability, capital adequacy and asset quality: core return on average tangible common equity (“Core ROATCE”), core return on average total assets, tangible common equity ratio and nonperforming assets to loans & other real estate owned. Core ROATCE was a change from previous years when core return on equity was used as one of the criteria. Banks were ranked on each metric. The rankings were added together to achieve a final score. The lower the score, the higher the ranking. Banks trading over-the-counter (“OTC”) were included. The smallest bank was about $1.9 billion in assets.

“I am very pleased to have the hard work of our talented banking team recognized through these prestigious rankings,” stated John Allison, Chairman and Founder of HOMB. “This is not just a popularity contest. These rankings are based on important metrics that measure the strength, performance and resilience of a financial institution, and we believe our inclusion reflects the disciplined approach and sustained results that have established HOMB among the top-performing banks in the industry,” continued Allison.

Home BancShares, Inc. is a bank holding company, headquartered in Conway, Arkansas. Its wholly-owned subsidiary, Centennial Bank, provides a broad range of commercial and retail banking plus related financial services to businesses, real estate developers, investors, individuals and municipalities. Centennial Bank has branch locations in Arkansas, Florida, Texas, Tennessee, South Alabama and New York City. The Company’s common stock is traded through the New York Stock Exchange under the symbol “HOMB.”

FOR MORE INFORMATION CONTACT:
Donna Townsell
Senior Executive Vice President &
Director of Investor Relations
(501) 328-4625

CONWAY, Ark., Sept. 18, 2026 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NYSE: HOMB) (“Home” or “the Company”), parent company of Centennial Bank (“Centennial”), today announced two recent performance recognitions.

First, on September 9, 2026, Forbes published their “World’s Top Performing Banks” list, and HOMB ranked #5 in Mid-Size Banks. Banks were evaluated across four main dimensions: profitability, growth & earnings quality, capital & funding resilience and asset quality & efficiency. Eligible banks were segmented into six tiers based on their total assets and then the scores were assigned. HOMB is among Tier 4 (mid-size banks) which have $20-$50 billion in assets. This is a new ranking by Forbes, and it is predicated on objective financial data obtained through leading data providers, such as S&P Capital IQ platform.

Second, on August 21, 2026, Bank Director published their annual “RankingBanking”, The Best U.S. Banks study, sponsored by Crowe LLP., and HOMB ranked #9 in the $5-$50 billion asset group and #18 among the top 25 publicity traded banks in the country. Data used in the 2026 RankingBanking analysis of the 300 largest publicly traded banks was collected through S&P Global Market Intelligence and analyzed by Piper Sandler & Co., using calendar year 2025 results. Four metrics were used to assess profitability, capital adequacy and asset quality: core return on average tangible common equity (“Core ROATCE”), core return on average total assets, tangible common equity ratio and nonperforming assets to loans & other real estate owned. Core ROATCE was a change from previous years when core return on equity was used as one of the criteria. Banks were ranked on each metric. The rankings were added together to achieve a final score. The lower the score, the higher the ranking. Banks trading over-the-counter (“OTC”) were included. The smallest bank was about $1.9 billion in assets.

“I am very pleased to have the hard work of our talented banking team recognized through these prestigious rankings,” stated John Allison, Chairman and Founder of HOMB. “This is not just a popularity contest. These rankings are based on important metrics that measure the strength, performance and resilience of a financial institution, and we believe our inclusion reflects the disciplined approach and sustained results that have established HOMB among the top-performing banks in the industry,” continued Allison.

Home BancShares, Inc. is a bank holding company, headquartered in Conway, Arkansas. Its wholly-owned subsidiary, Centennial Bank, provides a broad range of commercial and retail banking plus related financial services to businesses, real estate developers, investors, individuals and municipalities. Centennial Bank has branch locations in Arkansas, Florida, Texas, Tennessee, South Alabama and New York City. The Company’s common stock is traded through the New York Stock Exchange under the symbol “HOMB.”

FOR MORE INFORMATION CONTACT:
Donna Townsell
Senior Executive Vice President &
Director of Investor Relations
(501) 328-4625

SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance’s common stock to eighteen new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $10.02, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi^® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150